Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc filed a report showing several senior leaders acquiring small amounts of GSK ordinary shares through the company’s Share Reward Plan. On 2025-10-09, CEO Emma Walmsley acquired 14 ordinary shares (7 partnership and 7 matching shares) at £16.4083 per share on the London Stock Exchange. CFO Julie Brown, Group General Counsel James Ford, President Corporate Development David Redfern, President Global Supply Chain Regis Simard, President Global Affairs Philip Thomson, and ViiV Healthcare CEO and President Global Health Deborah Waterhouse each acquired 16 shares under the plan at the same price. SVP Global Communications Sally Jackson and SVP & Company Secretary Victoria Whyte each acquired 14 shares on the same terms.
GSK plc reports a share repurchase executed through BNP Paribas SA on 09 October 2025, acquiring 295,000 ordinary shares at an average price of 1,640.23p per share. The purchase is part of an existing buyback programme under a non-discretionary agreement announced on 30 September 2025. Since that announcement, the company has bought 2,549,000 ordinary shares.
After this transaction GSK will hold 250,013,844 ordinary shares in treasury and will have 4,065,394,695 ordinary shares in issue (excluding treasury), which is also the company's total number of voting rights. The company states that ordinary shares held in treasury represent 6.15% of voting rights.
GSK plc executed share repurchases on 08 October 2025, buying 308,000 ordinary shares at an average price of 1,622.48p per share; the trades were effected by BNP Paribas SA under a previously announced non‑discretionary agreement. Since 30 September 2025, the company has purchased 2,254,000 ordinary shares as part of its ongoing buyback programme. After the latest transactions GSK holds 249,718,844 ordinary shares in treasury and has 4,065,689,695 ordinary shares in issue (excluding treasury shares), giving a treasury share voting-rights equivalent of 6.14%. A detailed schedule lists individual executions, venues (BATE, XLON) and per-share prices ranging from 1,612.00p to 1,630.00p for the aggregated day, with multiple transaction references provided. The announcement reiterates a standard caution on forward-looking statements.
GSK plc executed further purchases of its ordinary shares on 07-October-2025, acquiring 354,000 shares at an average price of approximately 1,603.99p per share. These purchases were made through BNP Paribas SA under the non-discretionary agreement announced on 30-September-2025 and form part of the company’s ongoing buyback programme.
Since 30-September-2025 the company has bought a total of 1,946,000 ordinary shares. After the reported transactions GSK holds 249,410,844 shares in treasury and has 4,065,997,695 ordinary shares outstanding (excluding treasury), giving a total number of voting rights of 4,065,997,695 and treasury-held voting rights of 6.13%.
GSK plc announced that, through BNP Paribas SA acting as broker, it purchased 340,000 ordinary shares of 31 1/4 pence each on 06 October 2025 as part of its ongoing buyback programme under the previously disclosed non-discretionary agreement. Since 30 September 2025, the company has purchased 1,592,000 ordinary shares in total. The purchased shares will be held as treasury shares, taking the company's total treasury holding to 249,056,844 ordinary shares and leaving 4,066,351,695 ordinary shares in issue (excluding treasury), which equals the stated total number of voting rights. The company confirms that the ordinary shares held in treasury represent 6.12% of voting rights. A detailed schedule lists individual trades, prices (in GBp) and transaction references executed on the London Stock Exchange and CBOE Europe order books.
GSK plc executed purchases of its ordinary shares on 03 October 2025, acquiring 350,000 shares through BNP Paribas under its ongoing buyback programme. The disclosed per-share price range shows trades between 1,598.00p and 1,649.00p
Since 30 September 2025 the company has bought 1,252,000 ordinary shares in total. After this transaction GSK holds 248,716,844 shares in treasury and reports 4,066,691,695 ordinary shares in issue (excluding treasury shares), giving treasury shares a 6.12% share of total voting rights. Detailed execution-level prices and transaction references are provided for trades on XLON and BATE.
GSK plc disclosed a purchase of 335,000 ordinary shares on 02 October 2025 executed by BNP Paribas under its announced buyback programme. The announcement says the bought shares will be held as Treasury shares and that, since 30 September 2025, the Company has purchased a total of 902,000 ordinary shares.
Following this transaction the Company holds 248,366,844 ordinary shares in treasury and has 4,067,040,496 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,067,040,496 and the percentage of voting rights attributable to Treasury shares is 6.11%.
GSK plc reports that, acting through BNP Paribas SA, it purchased 262,000 ordinary shares of 31 3/4 pence each on 01 October 2025 as part of its existing buyback programme under the non-discretionary agreement announced on 30 September 2025. The announcement states that since 30 September 2025 the Company has purchased 567,000 ordinary shares. The purchased shares will be held as treasury shares. Following the purchase, GSK will hold 248,031,844 ordinary shares in treasury and will have 4,067,375,496 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,067,375,496, and the percentage of voting rights attributable to ordinary shares held in treasury is 6.10%. The filing includes a detailed schedule of individual trades executed on London exchanges and notes the purchase venues and aggregated trade information.
GSK plc notifies the market of its issued share capital and total voting rights. The company reported 4,315,407,340 ordinary shares of 31.25 pence each, of which 247,769,844 are held in treasury, producing a total of 4,067,637,496 voting rights. The notice states this figure may be used by shareholders as the denominator when determining whether they must notify changes in their holdings under applicable disclosure rules and provides an email contact for notifications.
GSK plc announced that, acting through BNP Paribas SA, it purchased 305,000 ordinary shares on 30 September 2025 as part of its existing buyback programme under a non-discretionary agreement with the Broker. The purchases will be held as Treasury shares. Following this transaction, GSK will hold 247,769,844 ordinary shares in treasury and have 4,067,637,496 ordinary shares in issue (excluding treasury shares), giving a total number of voting rights of 4,067,637,496. The Company confirms the percentage of voting rights attributable to treasury shares is 6.09%. The filing includes an aggregated trading-venue schedule and detailed individual transaction prices and reference numbers.